Breakthrough Compound Blocks Protein Interaction, Offering New Hope for Diabetes Treatment
Table of Contents
A novel compound, RAGE406R, has demonstrated the ability to limit cell death, reduce inflammation, and lessen organ damage associated wiht both Type 1 and Type 2 diabetes in preclinical studies, offering a potential new avenue for treatment.
Researchers at NYU Langone Health have identified a drug candidate that successfully prevents the interaction of two proteins – RAGE and DIAPH1 – a pairing that contributes to heart and kidney injury linked to diabetes and impedes wound healing. The findings, recently highlighted on the cover of Cell Chemical Biology, suggest a targeted approach to managing diabetic complications, rather than solely focusing on blood sugar control.
Targeting the Root of diabetic Complications
Current treatments for diabetes often address symptoms, but few tackle the underlying causes of long-term complications.According to a senior researcher involved in the study, “There are currently no treatments that address the root causes of diabetic complications, and our work shows that RAGE406R can — not by lowering the high blood sugar, but instead by blocking the intracellular action of RAGE.” This new approach focuses on interrupting a specific cellular process that drives damage in diabetic patients.
RAGE, or Receptor for Advanced Glycation End Products, is a protein that responds to molecules formed when proteins or fats bind to sugars – a process accelerated in diabetes. These molecules, known as AGEs, accumulate in the bloodstream and contribute to inflammation and tissue damage. Experiments revealed that RAGE406R effectively competes with DIAPH1 for a binding site on RAGE, disrupting a harmful interaction.
How RAGE and DIAPH1 Fuel Damage
DIAPH1 plays a crucial role in forming actin filaments,essential components of a cell’s internal structure. Researchers discovered that when DIAPH1 connects to RAGE, it intensifies the formation of actin structures, exacerbating diabetic complications. By blocking this connection, RAGE406R appears to ease swelling in diabetic tissues and promote more efficient repair.
The team previously screened over 58,000 molecules to identify those that could interfere with the RAGE-DIAPH1 pathway.An earlier candidate, RAGE229, raised safety concerns due to potential DNA-altering properties. RAGE406R was engineered to remove this structural element, resulting in a safer profile.
accelerated Wound Healing and Reduced Inflammation
Testing RAGE406R in obese mice with Type 2 diabetes – a widely used model for chronic diabetes complications – showed significant improvements in delayed wound healing. Applying the compound directly to the skin accelerated wound closure in both male and female mice.
The benefits of RAGE406R extend to the immune system. The compound lowered levels of CCL2, a signaling molecule that promotes inflammation. By calming inflammation in macrophages – a type of immune cell – RAGE406R supported structural remodeling in tissues, a vital part of the healing process.
“Our findings point to a promising new pathway for treating diabetes in the future,” stated a co-senior study author. “the current study results serve as a springboard for the growth of therapies for both types of diabetes, and for designing markers that can measure how well the new treatment works in live animals.”
Looking Ahead: Human Trials and Future Therapies
While these results are promising, further research is needed. The next step involves rigorous testing in human clinical trials to confirm the efficacy and safety of RAGE406R. If successful, this compound could fill critical gaps in diabetes treatment, especially for Type 1 diabetes, where current options are limited.
the research team included contributors from NYU Langone Health and the state University of New York (SUNY) at Albany, and also RJD Medicinal Chemistry and Drug Finding Consulting LLC. The work was supported by grants from the U.S. Public Health Service and the NYU Diabetes Research Program. Several researchers are listed on patent applications related to this research, managed in accordance with NYU Langone Health policies.
